Current Report Filing (8-k)
30 August 2016 - 1:40AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
August 29, 2016
PDL BioPharma, Inc.
(Exact name of Company as specified in its charter)
000-19756
(Commission File Number)
|
|
|
|
Delaware
|
|
94-3023969
|
(State or Other Jurisdiction of Incorporation)
|
|
(I.R.S. Employer Identification No.)
|
932 Southwood Boulevard
Incline Village, Nevada 89451
(Address of principal executive offices, with zip code)
(775) 832-8500
(Company’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
PDL BioPharma Announces the Successful Conclusion of its Debt Financing Agreement with Paradigm Spine
On August 29, 2016, PDL BioPharma, Inc. issued a press release regarding the successful conclusion of its debt financing agreement with Paradigm Spine, LLC. A copy of the press release is furnished hereto as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
|
|
|
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press Release
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
PDL BIOPHARMA, INC.
|
(Company)
|
|
|
|
By:
|
|
/s/ John P. McLaughlin
|
|
|
John P. McLaughlin
|
|
|
President and Chief Executive Officer
|
Dated:
August 29, 2016
Exhibit Index
|
|
|
|
Exhibit No.
|
|
Description
|
99.1
|
|
Press Release
|
PDL BioPharma (NASDAQ:PDLI)
Historical Stock Chart
From Apr 2024 to May 2024
PDL BioPharma (NASDAQ:PDLI)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about PDL BioPharma Inc (NASDAQ): 0 recent articles
More Pdl Biopharma, Inc. News Articles